Find the Perfect Plan for Your Investment Journey
M
Latest price
52 Week Range
A$0.88 - A$3.37
Next Earnings Date
Jul 29 2025 (Estimate)
Next Earnings Date
Jul 29 2025 (Est.)
Latest price
Market Cap | A$2.29B |
EV | A$2.43B |
Shares Outstanding | 1.30B |
Beta | 2.03 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | A$3.80 |
P/E 2025E | 15.75x |
P/Revenue 2025E | 67.26x |
Revenue | -5.20% |
EPS | 33.60% |
Operating Cash Flow | 21.20% |
Free Cash Flow | 21.50% |
Revenue | 270.40% |
EPS | - |
Operating Cash Flow | -7.40% |
Free Cash Flow | - |
Gross Margin 2025E | 87.40% |
Net Profit Margin 2025E | -367.89% |
ROE 2025E | -11.75% |
ROCE 2024 | -17.91% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
M
Mesoblast Limited
MSB
Sector
Healthcare
Industry
Biotechnology
CEO
Itescu, Silviu
Employees
73
Website
www.mesoblast.comIPO Date
2004-12-15
Headquarters
55 Collins Street, Level 38, Melbourne, Victoria, 3000, Australia
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved